Attendees will understand the early experience and clinical impact of GI multiplex PCR diagnostics in children

Similar documents
The Cost-effectiveness of a GI PCR panel in Detecting Necessary to Treat Infections

Advances in Gastrointestinal Pathogen Detection

The Changing Paradigm of the Laboratory Diagnosis of Gastroenteritis

Dear Healthcare Provider, The information contained here may be very important to your practice. Please take a moment to review this document.

PATHOGEN DETECTION WITH THE FILMARRAY

3base The Science Behind EasyScreen Molecular Diagnostic Assays. Nucleic Acid Conversion Technology

PAMET Continuing Education 2016

Food Microbiology 101

The Netherlands Donor Feces Bank a. it takes stool to get better

INFECTIOUS DISEASE. Page 2

Bacterial Enteropathogens Faecal PCR and Culture Results

DISCLOSURE Relevant relationships with commercial entities Wyeth (received advisory board & speaker honoraria) Potential for conflicts of interest wit

Potential Reimbursement CPT Codes

Chapter 1 The Public Health Role of Clinical Laboratories

Contractor Information

M O L E C U L A R G E N E T I C S

MolDX: Foodborne Gastrointestinal Panels Identified by Multiplex Nucleic Acid Amplification Tests (NAATs)

Culture-Independent Diagnostic Tests IMPACT ON INFECTIOUS DISEASE SURVEILLANCE

Diagnostics guidance Published: 11 January 2017 nice.org.uk/guidance/dg26

IDSA Diarrhea Guidelines. Larry Pickering, MD, FAAP, FIDSA, FPIDS

FOOD BORNE INFECTIONS

Detection of 23 Gastrointestinal Pathogens Among Children Who Present With Diarrhea

33. I will recommend this primer to my colleagues. A. Strongly Agree D. Disagree B. Agree E. Strongly Disagree C. Neither agree nor disagree

Disclosures. Curry Clinical Microbiology Updated 3/12/17

REVISED ESTIMATE OF FOOD-BORNE ILLNESS IN CANADA

54 MMWR March 17, Appendix B. Guidelines for Confirmation of Foodborne-Disease Outbreaks

2015 Update in Infectious Diseases: New Tools in Diagnostic Microbiology

3/18/ Update: STEC Diagnosis and Surveillance in Wisconsin. Objectives. Objectives. Shiga toxin-producing Escherchia coli (STEC)

2014 Update: STEC Diagnosis and Surveillance in Wisconsin

Gastrointestinal Pathogen Panel Guidance Authors: Trevor Van Schooneveld, MD, Kiri Rolek, PharmD, BCPS, Paul Fey PhD, Mark Rupp, MD

Patient: Ima Sample. Accession: Shiloh Rd, Ste 101. Collected: 9/4/2018. Received: 9/6/2018 Alpharetta GA

Virtual Lectures Planning Committee Disclosure Summary

Department of Laboratory Medicine, Nationwide Children's Hospital, Columbus, OH, USA

Hompes Method. Practitioner Training Level II. Lesson Seven Part A DRG Pathogen Plus Interpretation

The national surveillance of Clostridium difficile in Denmark

Bacterial Enteric Infections Detected by Culture-Independent Diagnostic Tests FoodNet, United States,

Acute Gastroenteritis

Patient: Ima Sample. Accession: Shiloh Rd, Ste 101. Collected: 2/10/2018. Received: 2/12/2018 Alpharetta GA

Meeting the Challenge of Changing Diagnostic Testing Practices and the Impact on Public Health Surveillance

Bacterial Enteric Pathogens: Clostridium difficile, Salmonella, Shigella, Escherichia coli, and others

Development and evaluation of user-developed protocols for bacterial respiratory pathogens leveraging the snap-load-go workflow of BD MAX TM

(3) Had a past illness from an infectious agent specified under paragraph (A)(1) of this rule; or:

Syndromic Testing: The right test, the first time.

A New Multiplex Real-time PCR Assay For Detection Of Intestinal Parasites

Test Catalog Updates August 3, 2016 Updates noted in Red

Microbiology, virology, immunology with the course of infectious diseases department, UzhNU

Laboratory Guide for Gastroenteritis Outbreaks. Public Health Laboratories Branch Ontario Agency for Health Protection and Promotion

Collection (Specimen Source Required on all tests) Sputum: >5 ml required. First morning specimen preferred.

Acute Gastroenteritis

Fecal Me This, Fecal Me That Where Are We Now With Giardia and Cryptosporidium Diagnostics?

Gastroenteritis. Mohamed Ahmed Fouad Lecturer of pediatrics Jazan faculty of medicine

WHO-Coordinated Global Rotavirus and Pediatric Diarrhea Surveillance

Pathogen specific exclusion criteria for people at increased risk of transmitting an infection to others

Adam Aragon Lisa Onischuk Paul Torres NM DOH, Scientific Laboratory Division

Epidemiology of Diarrheal Diseases. Robert Black, MD, MPH Johns Hopkins University

Shabnam Tehrani M.D., MPH Assistant Professor of Infectious Diseasese &Tropical Medicine Research Center, Shahid Beheshti University of Medical

Outer Membrane Vesicles: A Novel Particles for Next Generation Vaccine

Multiplex Syndromic Testing s Effect on Public Health Molecular Testing & Emerging Technology WCLN Workshop April 28, 2016

SC P. on POOP. Susan E. Sharp, Ph.D., DABMM Director of Microbiology Portland, OR

Produce Food Safety. Understand what you want to prevent

Gastrointestinal Disease from 2007 to 2014

Appendix 2: Enteric disease

for a germ-free environment

Food Borne Illnesses Be Gone!!

Foodborne Disease in the Region of Peel

New Mexico Emerging Infections Program Overview. Joan Baumbach NM Department of Health September 23, 2016

FOODBORNE INFECTIONS. Caroline Charlier-Woerther March 2017

Acute Gastroenteritis

Diarrhea in Nontravelers: Risk and Etiology

Clostridium difficile Infection (CDI) Management Guideline

Multiplex molecular testing for management of infectious gastroenteritis in a hospital setting: a comparative diagnostic and clinical utility study

Lesson 1.5. The Usual Suspects. Estimated time: Two 50 min periods. Instructional overview. Instructional objectives. Assessment

Gastroenteritis Outbreaks rev Apr 2017

Foodborne Outbreak of E. coli Infections and Hemolytic Uremic Syndrome in Germany, 2011

Diarrheal Diseases in Asia: overview and update. G. Balakrish Nair, PhD Ag. Regional Advisor Research Policy and Cooperation WHO, SEARO

Basic Epi: Differential Diagnosis of Foodborne Illnesses. One Foodborne Investigation Strategy. Second Strategy: Differential Diagnosis

RIDA GENE Viral Stool Panel II real-time RT-PCR

2/26/2009. Diarrhea. Christina Tennyson, M.D. Assistant Professor of Medicine Division of Gastroenterology Columbia University

Christina Tennyson, M.D. Division of Gastroenterology

GERMANY Population 1999: Population 2000: Area: km 2

The 12 Most Unwanted Bacteria

Waterborne Disease Risk.

Understanding the Public Health Significance of Salmonella. Betsy Booren, Ph.D. Director, Scientific Affairs

VIRAL GASTRO-ENTERITIS

MICROBIOLOGICAL TESTING IN PICU

Clinical Significance of Fecal Lactoferrin and Multiplex Polymerase Chain Reaction in Patients with Acute Diarrhea

RIDA GENE Parasitic Stool Panel II real-time PCR

RIDA GENE Dientamoeba fragilis real-time PCR

Diarrhea Evaluation & Management

The QIAsymphony RGQ as a platform for laboratory developed tests

Manual for Reporting of Food-borne Outbreaks in the framework of Directive 2003/99/EC 1

EHEC O111 O157

GI Bacterial Infections (part-1)

The GI Microbial Assay Plus GI-MAP. Multiplex DNA Stool Technology for the Integrative and Functional Medicine Practitioner

Laboratory Investigation of. Infectious Diarrhoea. Quiz Feedback. bpac nz better medicine

Foodborne Illness and Its Impact

Gastrointestinal Infections in Northern Ireland

Gastroenteritis. Presenter: J.J. Kambona (M.B.Ch.B; M.Med)

H E A L T H & R E S E A R C H. Innovating the future

The Burden of Disease Caused by Enteric Pathogens. Martyn Kirk for the Enteric Diseases Taskforce

Transcription:

Participants will understand the role of a comprehensive business case in considering the introduction of novel technology affecting multiple areas of the laboratory Attendees will learn about the impact on the laboratory of the introduction of a multiplex assay that will replace various components of conventional GI pathogen diagnostics Attendees will understand the early experience and clinical impact of GI multiplex PCR diagnostics in children

Pfizer Unrestricted educational grant for study of neonatal candidiasis Astellas Site PI clinical trial of micafungin in neonatal candidiasis Luminex Molecular Diagnostics In kind support for xtag GPP assay evaluation

370 bed pediatric hospital affiliated with University of Toronto General pediatrics Emergency Surgery General, cardiac, neurosurgery, orthopedics Critical care unit Neonatal intensive care unit Oncology / Bone marrow transplantation Solid organ transplantation Kidney, heart, liver, lung, small bowel Dialysis Burn Unit Trauma Center Cystic Fibrosis Center (n=300)

Bacterial culture and susceptibility Salmonella, Shigella, Yersinia enterocolitica, Campylobacter jejuni/coli, E. coli 0157:H7, (Aeromonas/Plesiomonas) Ova and parasites Refer to public health laboratory Virus detection by electron microscopy Rotavirus, adenovirus, torovirus, calicivirus, astrovirus, norovirus Clostridium difficile toxin detection Tissue culture cytotoxin assay until late 2011 C. difficile PCR subsequently

Bacterial C&S Stool in Carey-Blair transport medium O&P EM Stool in preservative Stool in empty sterile container C. difficile PCR Stool in empty sterile container

Bacteriology C. difficile PCR O&P 0.5 FTE send-out and results return Virology 0.5 FTE

Bacterial culture Electron microscopy Ova and parasites C. difficile cytotoxin assay C. difficile PCR 6.6% 7.1% 1.7% 8.0% 13.5%

Advantages Inexpensive reagents Modifiable detection conditions Susceptibility testing Clinical suspicion directs investigation May include organisms not on molecular panels (e.g. some viruses parasites) Gold standard Disadvantages Labour-intensive Widely varying technical expertise required EM purchase and maintenance expense Clinical suspicion directs investigation Unusual, uncultivable or difficult to detect organisms may not be diagnosed

Improved sensitivity of detection, with good specificity Single test for GI pathogens across organism boundaries Resource rationalization Rapid diagnosis Diagnosis of clinically unsuspected pathogens Ability to detect co-infections Infection control of nosocomial diarrhea (viruses and C. difficile) Public health outbreak pathogen identification

May lack certain targets of interest Viruses Torovirus (33% of viruses @ SickKids) Calicivirus Astrovirus Sapovirus Parasites Dientamoeba fragilis (77% parasites @ SickKids) Lack susceptibility data Require fully developed and experienced molecular lab Cost

Bacteria Salmonella spp. Shigella spp. Campylobacter jejuni/coli Yersinia enterocolitica E. coli 0157:H7 Non-0157 shiga-toxin producing E. coli (STEC, EHEC) Clostridium difficile toxin A/B Enterotoxigenic E. coli Vibrio cholerae Viruses Rotavirus A Adenovirus 40/41 Norovirus GI/II Parasites Giardia lamblia Entamoeba histolytica Cryptosporidium

Bacteria Salmonella spp. Shigella spp. Campylobacter spp. Vibrio spp. C. difficile toxin B C. perfringens Y. enterocolitica Aeromonas spp. E. coli 0157:H7 VT-producing E. coli Viruses Rotavirus Norovirus GI/GII Adenovirus 40/41 Astrovirus Not on panel Parasites ETEC

Gastrofinder Smart 17 Fast (Pathofinder, Netherlands) Similar to Seegene assay plus parasites (including D. fragilis) Prodesse ProGastro SSCS (Hologic MDx) (FDA approved) Salmonella, Shigella, Campylobacter, Shiga Toxin 1 (stx1) and Shiga Toxin 2 (stx2) genes

48 reference isolates, 254 clinical specimens (stool Carey- Blair, raw) Culture, EIA/IC, microscopy and single-plex PCR as comparator Discrepant analysis: comparator method Overall sensitivity 94.5%, specificity 99% 100% sens: adenovirus, norvirus, rotavirus, V. cholerae, Y. enterocolitica, E. histolytica, Cryptosporidium spp., E. coli O157:H7 94-5% sens: G. lamblia, ETEC, STEC 92-3% sens: Shigella, Salmonella 90-1% sens: C. difficile, C. jejuni 12.2% co-infections ETEC/STEC, Salmonella, G. lamblia, C. difficile, C. jejuni, rotavirus Inhibition 8% Discrepant 13.4%, without E. histolytica 4%

440 stools (1/2 children) Comparator conventional assays Culture Salmonella, Shigella, Campylobacter, Y. enterocolitica, V. cholerae, pathogenic E. coli serovars (children), toxigenic C. difficile (children) EIA/IC Rotavirus, adenovirus, norovirus, CD toxin PCR (EHEC) Microscopy (parasites) More sensitive than conventional (p 0.01) Rotavirus, norovirus, Salmonella, Campylobacter, C. difficile toxin 176 positive (40%) Viruses (23%) Bacteria (14%) Parasites (2.9%) 7% co-infections Discrepants not analyzed

450 stools (2012) Comparator conventional assays Culture Salmonella, Shigella, Campylobacter, E. coli O157:H7 (not Yersinia) EIA/IC: CD (GDH and toxin), norovirus, adenovirus, rotavirus Virus discrepants (single-plex PCR) Microscopy (parasites) CD PCR Prevalence 8% conventional 26% GPP Norovirus 4-fold increase, confirmed by single-plex PCR Rotavirus and adenovirus confirmed by single-plex PCR Co-infections 10% 2200 stools (2013) 48% of diagnosed infections were not suspected by clinician primarily viral and parasitic, i.e. test not requested Decreased TAT (bacteria and parasites) Predicted decreased isolation days

167 frozen selected stools (65 pos) 20 bacterial culture pos Salmonella (8), C. jejuni (5), E. coli O157 (3), Y. enterocolitica (1), Shigella sonnei (1) 14 EM virus pos Adenovirus (5), rotavirus (6), norovirus (3) 25 CD PCR pos 6 O&P pos (PHL) Giardia (1), E. histolytica (5) 102 negative stools 40 cult neg, 37 EM neg, 25 CD neg Easymag extraction GPP panel on Luminex 100 instrument

65 positive stools 6/65 false negative 3/6 repeated positive 3/65 false negative (4.6%) 95.4% sensitivity vs. conventional tests

GPP negative for all targets tested Adenovirus 7 (1) Aeromonas hydrophila (1) torovirus (3) astrovirus (3) calicivirus (2) E. dispar (4)

Stool C&S pos (21) CD (7) norovirus (9) rotavirus (1) Stool C&S neg (40) norovirus (9) CD (5) rotavirus (1) Stool EM pos (25) CD (3) Stool EM neg (37) CD (3) norovirus (5) rotavirus (1) Campylobacter (1) Stool CD pos (25) norovirus (7) Giardia (1) Stool CD neg (25) norovirus (2) CD (2) Campylobacter (1) Stool O&P pos (10) norovirus (1) Giardia (1) CD (1) Total 57 unsuspected GI pathogens

Target Strain SickKids LoD Luminex LoD STEC E. coli O84:HNM, O101:HNM, O111:HNM, O103:H2 9 x10 3 7 x10 5 CFU/ml 9 x10 5 CFU/ml V. cholerae non-o1 non-o139, O139 [O1 El Tor (Inaba)] 1 x10 5 3 x10 7 plasmid copy/ml 1.3 x10 3 plasmid copy/ml ETEC E. coli O49:HNM 1 x10 4 CFU/ml 1.5 x10 7 CFU/ml Y. enterocolitica biogrp 3 serotype 3, biogrp 5 Campylobacter spp. 1.7 x10 6 1.5x10 7 CFU/ml 1.4 x10 8 CFU/ml Campylobacter coli 3 x10 2 CFU/ml 6 x10 4 CFU/ml Shigella spp. S. dysenteriae type 1, S. boydii type 1 1.3 x10 3 CFU/ml 3.3 x10 4 CFU/ml

Elucidate clinical and microbiological rationale Advantages for patient care Advances and efficiencies for the laboratory Estimate test # Single multiplex test predicted to reduce testing volume by ~50% if used exclusively GPP vs. C&S + EM + CD + O&P Define testing algorithm Outpatients and inpatients 4 days: GPP Inpatients >4 days: CD PCR single-plex + EM Determine conventional testing required Bacterial culture, EM, CD single-plex PCR, (norovirus singleplex PCR?) Determine equipment (incl. service contracts) and reagent costs Conventional low GPP high

Determine human resource requirements Conventional 1.0 FTE GPP 0.5 FTE Identify risks and dependencies Obtain stakeholder input and support Pediatrics Infectious Diseases Infection Prevention and Control Perform financial analysis and implications Develop formal business plan Negotiate contract

Stool should be tested for infectious pathogens when 3 loose stools in 24 hours Should take the shape of the container Difficult to assess in laboratory due to receipt in Carey-Blair transport medium Stool should not be sent after a single loose stool Drugs Osmotic diarrhea Diet Stool should be sent in Carey-Blair transport medium so that culture can be attempted if GPP positive

Gl multiplex PCR (GPP) Performed 4 times per week Negative or positive results not repeated except after approval by the Microbiologist C. difficile PCR results not reported on children 1year Stool positive by GPP for Y. enterocolitica, Salmonella and Shigella will be cultured to enable susceptibility testing Ova and parasite microscopic examination If GPP negative and a high index of suspicion for parasitic infection Conventional microscopy (need O&P container with preservative)

C. difficile toxin PCR Performed 3 times per week Not performed until one week after negative GPP Repeat accepted weekly if previous CD PCR negative C. difficile PCR results not reported on children 1year of age Electron microscopy for viruses GPP rejected unless approved by microbiologist

182 stools tested 47 stools pos (25.8%) 53 targets pos (29.1%) Bacteria Salmonella (3) Yersinia enterocolitica (3) Camplybacter spp. (5) E. coli O157:H7 (1) ETEC (2) C. difficile toxin A/B (23) Viruses Adenovirus (5) Norovirus (9) Parasites Giardia lamblia (1) Cryptosporidium spp. (1) 32 (26%) cancelled, outside of protocol 2/3 confirmed by culture 3/3 confirmed by culture Co-infections 10.6% stools (5/47) Adeno + CD + Campy Campy + Giardia CD + noro CD + Campy Noro + Campy Inhibition 2.2% stools (4/182) ¾ repeat no inhibition

Bacterial culture Electron microscopy Ova and parasites C. difficile cytotoxin assay C. difficile PCR Luminex xtag GPP (1 st 6 weeks) C. difficile (GPP or single-plex) Co-infections (5) 6.6% 7.1% 1.7% 8.0% 13.5% 29.1% (25.8% pts) 11.8% 10.6%

Training all technologists on new assay Excellent support from LMD Requirement for all steps to proceed without interruption and for use of cold blocks for manipulation of reagents, to avoid false positives Determination of threshold to repeat testing if multiple targets identified Interpretation of low MFI results for certain targets Norovirus and Salmonella Education of clinicians regarding new testing algorithm and implications of testing

Introduction of GPP has increased the rate of detection of all classes of enteric pathogens in children, over conventional methods, with excellent sensitivity and specificity Different algorithms for community-acquired and nosocomial diarrhea have focused GPP testing on the population at greatest need of very broad testing Enabled by in-house EM and CD PCR Replacement of conventional diagnostic methods with GPP can be achieved without increased cost, but probably requires efficiencies attained by reducing human resources

Farhad Gharabaghi Karan Greenock Fern Parisian Nursrin Dewsi John Nishikawa Microbiology technologists Astrid Petrich Yvonne Yau David Polchert